This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Araclon Biotech S.L.
Drug Names(s): amyloid beta peptide vaccine 42
Description: ABvac42 is an active immunotherapy against the beta-amyloid 42 protein. The removal of this excess beta amyloid and pathological prevents the formation of amyloid plaques in the brain that produce neurodegeneration.
Deal Structure: In March 2012, Grifols announced that they acquired 51% of the equity of Zaragoza-based company Araclon Biotech.
Partners: Grifols, S.A.
Additional information available to subscribers only: